<DOC>
	<DOCNO>NCT02221830</DOCNO>
	<brief_summary>Evaluation efficacy postpartum 24 hour oxytocin infusion reduce blood loss patient pre-eclampsia ( PE )</brief_summary>
	<brief_title>Postpartum Hemorrhage Prevention Patients With Preeclampsia ( PHP3 Study )</brief_title>
	<detailed_description>The overall goal study evaluate efficacy postpartum 24 hour oxytocin infusion prevention-oriented strategy reduce blood loss patient pre-eclampsia ( PE ) blind , placebo control , randomize control trial .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1. vaginal cesarean delivery gestational age great equal 20 week gestational age ; 2. diagnosis preeclampsia ( PE define use standard definition base ACOG bulletin NIH Working Group High Blood Pressure Pregnancy ( i.e. , systolic blood pressure great 140 mm Hg diastolic blood pressure great 90 mm Hg least 2 occasion least 6 hour apart 20 week gestation proteinuria &gt; 300mg per 24 hour period &gt; 1+ dipstick ) . 3. patient treated magnesium sulfate 24 hour post partum 2g/hr ( standard care deem appropriate clinician seizure prophylaxis ) 1. abnormal placentation ( previa , accreta , etc ) 2. antenatal hemorrhage 3. contraindication oxytocin</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>